ViiV Healthcare’s HIV Treatment Still Effective With Fewer Doses

GlaxoSmithKline-owned ViiV Healthcare and J&J’s Janssen presented results from a joint Phase III clinical study showing that their long-acting HIV drugs, cabotegravir and rilpivirine, remain effective even with less frequent dosing, according to a statement.
Read More

Leave a Reply

%d bloggers like this: